Extrait

The primary objective of this study is to demonstrate the opioid-sparing efficacy of parecoxib 40 mg i.v. given as a loading dose followed by 20 mg i.v. in the 24 hours after the end of surgery.

Critère d'inclusion

• Patients who are scheduled to undergo routine radical prostatectomy performed under a standardized regimen of general anesthesia, and who are expected to experience moderate to severe postsurgical pain in the absence of postoperative analgesia

Liens

• ictrp
• euctr